SCHEMBL2904791

SCHEMBL2904791

CC(C)(C)OC(=O)N1CCN(C(c2ccc(-c3cccc(F)c3)cc2)c2c[nH]nc2-c2ccco2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.42
CYP3A5 P20815 2/20 0.42
ABCB1 P08183 2/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
ADORA2A P29274 4/20 0.39
GPR119 Q8TDV5 2/20 0.39
ADORA1 P30542 1/20 0.37
CRBN Q96SW2 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
LMNA P02545 2/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
TGFBR1 P36897 1/20 0.36
CTSS P25774 1/20 0.34
CTSK P43235 1/20 0.34
TBK1 Q9UHD2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2902713 0.93 CYP3A4 (0.42) CYP3A4CYP3A5ABCB1ABCG2ADORA2A
SCHEMBL2910374 0.89 ALDH1A1 (0.41) CYP3A4LMNAKDM4ENPC1USP2
SCHEMBL2908989 0.87 KMT2A (0.44) CYP3A4CYP3A5ABCB1ABCG2ADORA2A
SCHEMBL2901965 0.87 SCD5 (0.42) CYP3A4CYP3A5ABCB1ABCG2ADORA2A
SCHEMBL2908049 0.86 ALDH1A1 (0.46) CYP3A4CYP3A5ABCB1ABCG2ADORA2A
SCHEMBL2903067 0.83 OPRD1 (0.37) ABCB1
SCHEMBL2902357 0.82 HRH3 (0.37) CYP3A4LMNAKDM4ENPC1USP2
SCHEMBL2905980 0.81 ALDH1A1 (0.42) CYP3A4LMNAKDM4ENPC1USP2
Morpholine SCHEMBL2905731 0.80 OPRD1 (0.35) ABCB1LMNA
SCHEMBL2902229 0.76 SMN1; SMN2 (0.47) LMNAKDM4ENPC1USP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP disclosed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A CYP3A4 451/4885CYP3A5 241/4885ABCB1 821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.